- Cel-Sci press release (CVM): FY research and development expenses were $15.9 million, which decreased by approximately $2.3 million, or 13%, compared to the year ended September 30, 2024.
- Net loss available to common shareholders decreased by $2.2 million to approximately $25.4 million for the twelve months ended September 30, 2025 from $27.6 million in fiscal 2024.
- The operating cash expenditures for the year were approximately $17.1 million.
Follow us on Google for the latest stock news